This article is more than 5 years old. Information may no longer be current.
Macular translocation a viable treatment for patients with non-AMD submacular disease
Retina. 2011;31(7):1337-1346.
Click Here to Manage Email Alerts
Macular translocation surgery 360 may be considered for patients with progressive bilateral vision loss from conditions other than age-related macular degeneration once other treatment options have been exhausted, according to a study.
The retrospective, consecutive case review assessed 16 patients who underwent macular translocation surgery 360. Subjects had severe functional limitations prior to surgery and a low probability for visual improvement without further intervention. Macular translocation was only considered once anti-VEGF agents had been determined to offer no further benefit.
Participants had undergone macular translocation surgery 360 for diseases including angioid streaks, pathologic myopia, Best disease, punctuate inner choroidopathy, presumed ocular histoplasmosis syndrome, central serous chorioretinopathy, adult-onset vitelliform macular dystrophy and North Carolina macular dystrophy.
Mean preop visual acuity was 20/135. Mean follow-up was 28 months, and mean postop visual acuity was 20/110. Outcomes varied substantially, with 38% of eyes gaining more than three lines and 25% losing more than three lines. However, 31% of patients achieved a final visual acuity of 20/50 or better.
Complications were common, including epiretinal membrane in 50% of patients, cystoid macular edema in 31%, residual diplopia in 25%, retinal detachment in 13% and recurrent choroidal neovascularization in 13%.